Frontotemporal Dementia

Neurology·MeSH: Frontotemporal Dementia

Prevalence

5.0 / 100K

14 drugs in development·7 companies·9 clinical trials

Drug Pipeline by Phase

Phase 3(3)

Drug	Company
Latozinemab (AL001)	Alector, Inc. (ALEC)
Open label - AL001	Alector, Inc. (ALEC)
otl-204	Orchard Therapeutics plc (ORTX)

Phase 2(3)

Drug	Company
AL001	Alector, Inc. (ALEC)
ANAVEX® 3-71 (AF710B)	ANAVEX LIFE SCIENCES CORP. (AVXL)
DNL593	Denali Therapeutics Inc. (DNLI)

Phase 1(4)

Drug	Company
ANAVEX®3-71	ANAVEX LIFE SCIENCES CORP. (AVXL)
LY3884963	ELI LILLY & Co (LLY)
Optional Sirolimus	ELI LILLY & Co (LLY)
Sirolimus	ELI LILLY & Co (LLY)

Phase 1/Phase 2(4)

Drug	Company
ly3884963	Prevail Therapeutics Inc. (PRVL)
optional sirolimus	Prevail Therapeutics Inc. (PRVL)
pbft02	Passage BIO, Inc. (PASG)
pr006	Prevail Therapeutics Inc. (PRVL)

BioSniper tracks 14 drugs in development for Frontotemporal Dementia across 7 companies.

There are 9 clinical trials targeting Frontotemporal Dementia tracked by BioSniper.

The estimated prevalence of Frontotemporal Dementia is approximately 5.0 per 100,000 population.

Full trial data, competitive analysis, and AI-powered pipeline tracking.